Entrada Therapeutics Says FDA Declines To Lift Clinical Hold On ENTR-601-44 IND Application
(RTTNews) - Biopharmaceutical company Entrada Therapeutics, Inc. (TRDA) announced Wednesday the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
Entrada plans to announce data from ENTR-601-44-101 in the second half of 2024.
The primary objective of Entrada's double-blind, single ascending dose Phase 1 clinical trial, which is expected to enroll approximately 40 participants, is to evaluate the safety and tolerability of a single dose of ENTR-601-44 in healthy male volunteers.
ENTR-601-44-101 will also evaluate pharmacokinetics and target engagement, as measured by exon skipping in the skeletal muscle.
Entrada was previously notified by the FDA that the IND for the Phase 1 clinical trial of ENTR-601-44 had been placed on clinical hold.
Despite providing additional information to the FDA, the Company was informed that the Agency declined to lift the clinical hold.
FTSE 100 Down 0.4% In Cautious Trade
CAC Up Slightly; Pernod Ricard Rises On Earnings
DAX Retreats After Firm Start, Down Marginally
Swiss Franc Rises Against Majors
Sensex, Nifty Retreat On US Tariff Worries
Bank Of Korea Stands Pat On Rates, Lifts 2025 Growth Outlook
European Shares Mostly Higher As Nvidia Outlook Lifts Sentiment
